Lyell Immunopharma Inc (LYEL)

$9.75 -0.02 (-0.20%)
Market Cap 144.67M
Revenue (ttm) 60,000.00
Net Income (ttm) -342.99M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -571,650.00%
Debt to Equity Ratio 0.00
Volume 23,400
Avg Vol 155,995
Day's Range N/A - N/A
Shares Out 14.81M
Stochastic %K 63%
Beta -0.24
Analysts Hold
Price Target $11.00

Company Profile

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company develops therapies using various approaches, such as c-Jun overexpression and NR4A3 gene knockout, to endow functional resistance to exhaustion; Epi-R to generate population of stem-like T cells with reduced exhaustion and improved proliferation and antitumor activity; CD62L positive enrichment...

Industry: Biotechnology
Sector: Healthcare
Phone: (650) 695-0677
Address:
201 Haskins Way, South San Francisco, United States
Polip
Polip Jul. 9 at 1:59 PM
$LYEL sad to see Lyell left behind in this biotech comeback. it's going to be seen. It;s a matter of time. 140M market cap with 300M in the bank $XBI
1 · Reply
fantastex
fantastex Jul. 6 at 2:27 PM
$LYEL Is this the week?
0 · Reply
fantastex
fantastex Jul. 1 at 12:17 PM
$LYEL news or no volume here.. Let's
0 · Reply
Polip
Polip Jun. 30 at 12:39 PM
$ABBV buys CAPSTAN TX a pre clinical CAR T company for 2 Billion dollars. This is huge for other Car T and cell therapy companies. VALUATION RESET $LYEL $KYTX $IOVA
1 · Reply
fantastex
fantastex Jun. 28 at 6:13 PM
$LYEL on Friday It traded over 12x relative volume.....
0 · Reply
fantastex
fantastex Jun. 27 at 3:34 PM
$LYEL from -4% to over 9... Highly manipulated price. After 1st of July we go higher .
0 · Reply
fantastex
fantastex Jun. 27 at 2:35 PM
$LYEL as said by @Peterson28 we should be patient and wait for better news. I honestly think that we'll get some sort of partnership later this year and or buyout rumors (reverse merger with $BMY ). They can easily scoop up this company for 500m in a glance. My target is 35. (23+50%premium)
0 · Reply
Peterson28
Peterson28 Jun. 26 at 3:22 AM
$LYEL The only loss making position this year but I am a very patient investor. Still expect a pump to $100 this year.
1 · Reply
JarvisFlow
JarvisFlow Jun. 24 at 11:30 AM
HC Wainwright & Co. has updated their rating for Lyell Immunopharma ( $LYEL ) to Neutral with a price target of 10.
0 · Reply
QuiverQuant
QuiverQuant Jun. 23 at 11:16 PM
Lyell Immunopharma to Discuss Clinical Data on LYL314 at H.C. Wainwright's "HCW@Home" Series Read more on $LYEL: https://www.quiverquant.com/news/Lyell+Immunopharma+to+Discuss+Clinical+Data+on+LYL314+at+H.C.+Wainwright%27s+%22HCW%40Home%22+Series?utm_campaign=stocktwits
0 · Reply
Latest News on LYEL
Lyell Immunopharma to Participate in the H.C. Wainwright “HCW@Home” Series

Jun 23, 2025, 5:00 PM EDT - 18 days ago

Lyell Immunopharma to Participate in the H.C. Wainwright “HCW@Home” Series

Lyell Immunopharma Announces Positive New Clinical Data Demonstrating High Rates of Durable Complete Responses from the Phase 1/2 Trial of LYL314 for the Treatment of Aggressive Large B-cell Lymphoma

Jun 17, 2025, 6:30 AM EDT - 24 days ago

Lyell Immunopharma Announces Positive New Clinical Data Demonstrating High Rates of Durable Complete Responses from the Phase 1/2 Trial of LYL314 for the Treatment of Aggressive Large B-cell Lymphoma

Lyell Immunopharma Strengthens Clinical and Commercial Capabilities with Key Board and Executive Appointments

Jun 9, 2025, 4:05 PM EDT - 4 weeks ago

Lyell Immunopharma Strengthens Clinical and Commercial Capabilities with Key Board and Executive Appointments

Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference

Jun 4, 2025, 4:05 PM EDT - 5 weeks ago

Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference

Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2025

May 13, 2025, 4:05 PM EDT - 2 months ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2025

Lyell Immunopharma Announces Oral Presentation of New Clinical Data from the Phase 1/2 Trial of LYL314 for the Treatment of Large B-cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) 2025

May 1, 2025, 9:00 AM EDT - 2 months ago

Lyell Immunopharma Announces Oral Presentation of New Clinical Data from the Phase 1/2 Trial of LYL314 for the Treatment of Large B-cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) 2025

Lyell Immunopharma Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for LYL314 for the Treatment of Relapsed and/or Refractory Large B-Cell Lymphoma

Apr 15, 2025, 9:00 AM EDT - 3 months ago

Lyell Immunopharma Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for LYL314 for the Treatment of Relapsed and/or Refractory Large B-Cell Lymphoma

Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2024

Mar 11, 2025, 4:05 PM EDT - 4 months ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2024

Lyell Immunopharma Announces Participation in Upcoming Investor Conferences

Feb 18, 2025, 4:05 PM EST - 5 months ago

Lyell Immunopharma Announces Participation in Upcoming Investor Conferences

Lyell to Highlight Vision for its Next-Generation CAR T-Cell Therapy Pipeline at 43rd Annual JP Morgan Healthcare Conference

Jan 9, 2025, 9:00 AM EST - 6 months ago

Lyell to Highlight Vision for its Next-Generation CAR T-Cell Therapy Pipeline at 43rd Annual JP Morgan Healthcare Conference

Lyell Presents Positive Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the Treatment of B-cell Lymphoma at the 2024 ASH Annual Meeting

Dec 9, 2024, 9:00 PM EST - 7 months ago

Lyell Presents Positive Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the Treatment of B-cell Lymphoma at the 2024 ASH Annual Meeting

Lyell Announces Presentation of Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the treatment of B-cell Lymphoma at the 2024 American Society of Hematology (ASH) Annual Meeting

Nov 5, 2024, 9:30 AM EST - 8 months ago

Lyell Announces Presentation of Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the treatment of B-cell Lymphoma at the 2024 American Society of Hematology (ASH) Annual Meeting

Lyell Immunopharma Completes Acquisition of ImmPACT Bio

Oct 31, 2024, 4:00 PM EDT - 9 months ago

Lyell Immunopharma Completes Acquisition of ImmPACT Bio

Lyell Immunopharma: Oversold And Poised For A Turning Point To Growth

Oct 25, 2024, 9:24 AM EDT - 9 months ago

Lyell Immunopharma: Oversold And Poised For A Turning Point To Growth

Lyell Immunopharma to Acquire ImmPACT Bio and Prioritizes its Pipeline to Focus on Next-Generation CAR T-cell Therapies

Oct 24, 2024, 4:00 PM EDT - 9 months ago

Lyell Immunopharma to Acquire ImmPACT Bio and Prioritizes its Pipeline to Focus on Next-Generation CAR T-cell Therapies

Lyell Immunopharma Announces the Acceptance Abstracts for Presentation at 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Oct 4, 2024, 9:00 AM EDT - 10 months ago

Lyell Immunopharma Announces the Acceptance Abstracts for Presentation at 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Lyell Immunopharma Announces Participation in Goldman Sachs Cell Therapy Day

Sep 24, 2024, 4:05 PM EDT - 10 months ago

Lyell Immunopharma Announces Participation in Goldman Sachs Cell Therapy Day

Lyell Immunopharma Announces Participation in September Investor Conferences

Aug 28, 2024, 4:05 PM EDT - 11 months ago

Lyell Immunopharma Announces Participation in September Investor Conferences

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2024

Aug 7, 2024, 4:05 PM EDT - 1 year ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2024

Lyell Immunopharma Reports Dose-dependent Clinical Activity from Phase 1 Trial of LYL797, a ROR1-targeted CAR-T Cell Product Candidate Enhanced with its Proprietary Anti-exhaustion Technology

Jun 26, 2024, 7:00 AM EDT - 1 year ago

Lyell Immunopharma Reports Dose-dependent Clinical Activity from Phase 1 Trial of LYL797, a ROR1-targeted CAR-T Cell Product Candidate Enhanced with its Proprietary Anti-exhaustion Technology

Lyell Immunopharma to Participate in BofA Securities Health Care Conference

May 7, 2024, 4:05 PM EDT - 1 year ago

Lyell Immunopharma to Participate in BofA Securities Health Care Conference

Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2024

May 6, 2024, 8:00 AM EDT - 1 year ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2024

Lyell Immunopharma: Testing The T-Cell Thesis With 2 Upcoming Data Catalysts

Apr 16, 2024, 6:25 PM EDT - 1 year ago

Lyell Immunopharma: Testing The T-Cell Thesis With 2 Upcoming Data Catalysts

Lyell Immunopharma Announces the Acceptance of Three Abstracts for Presentation at 2024 AACR Annual Meeting

Mar 5, 2024, 4:30 PM EST - 1 year ago

Lyell Immunopharma Announces the Acceptance of Three Abstracts for Presentation at 2024 AACR Annual Meeting

Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2023

Feb 28, 2024, 4:05 PM EST - 1 year ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2023

Lyell Immunopharma Announces Participation in March Investor Conferences

Feb 26, 2024, 4:05 PM EST - 1 year ago

Lyell Immunopharma Announces Participation in March Investor Conferences

Lyell Immunopharma to Participate in 42nd Annual J.P. Morgan Healthcare Conference

Jan 3, 2024, 4:05 PM EST - 1 year ago

Lyell Immunopharma to Participate in 42nd Annual J.P. Morgan Healthcare Conference

Lyell Immunopharma: Potential Solid Tumor Targeting With CAR-T And TIL

Nov 10, 2023, 2:23 PM EST - 1 year ago

Lyell Immunopharma: Potential Solid Tumor Targeting With CAR-T And TIL

Lyell Immunopharma Receives FDA Orphan Drug Designation for LYL845 for the Treatment of Melanoma

Nov 9, 2023, 4:05 PM EST - 1 year ago

Lyell Immunopharma Receives FDA Orphan Drug Designation for LYL845 for the Treatment of Melanoma

Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2023

Nov 7, 2023, 4:05 PM EST - 1 year ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2023

Lyell Immunopharma Announces the Acceptance of Six Abstracts for Presentation at 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Sep 27, 2023, 9:00 AM EDT - 1 year ago

Lyell Immunopharma Announces the Acceptance of Six Abstracts for Presentation at 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Cellares and Lyell to Evaluate Automated Manufacturing of Lyell's CAR T-Cell Therapy on Cellares' Cell Shuttle Platform

Sep 11, 2023, 8:00 AM EDT - 1 year ago

Cellares and Lyell to Evaluate Automated Manufacturing of Lyell's CAR T-Cell Therapy on Cellares' Cell Shuttle Platform

Lyell Immunopharma to Participate in Upcoming Investor Conferences

Aug 31, 2023, 4:05 PM EDT - 2 years ago

Lyell Immunopharma to Participate in Upcoming Investor Conferences

Lyell Immunopharma: Once Huge IPO Now Waiting For Clinical Data

Aug 26, 2023, 9:29 AM EDT - 2 years ago

Lyell Immunopharma: Once Huge IPO Now Waiting For Clinical Data

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2023

Aug 8, 2023, 4:05 PM EDT - 2 years ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2023

Lyell Immunopharma Appoints Matthew Lang as Chief Business Officer

Jul 5, 2023, 4:05 PM EDT - 2 years ago

Lyell Immunopharma Appoints Matthew Lang as Chief Business Officer

Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2023

May 4, 2023, 4:05 PM EDT - 2 years ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2023

Lyell Immunopharma to Participate in BofA Securities Healthcare Conference

May 2, 2023, 4:05 PM EDT - 2 years ago

Lyell Immunopharma to Participate in BofA Securities Healthcare Conference

Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2022

Feb 28, 2023, 4:05 PM EST - 2 years ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2022

Lyell Immunopharma to Participate in 41st Annual J.P. Morgan Healthcare Conference

Jan 3, 2023, 4:05 PM EST - 2 years ago

Lyell Immunopharma to Participate in 41st Annual J.P. Morgan Healthcare Conference

Lyell Immunopharma Appoints Lynn Seely, MD as President and Chief Executive Officer

Dec 15, 2022, 7:00 AM EST - 2 years ago

Lyell Immunopharma Appoints Lynn Seely, MD as President and Chief Executive Officer

Lyell Immunopharma to Participate in BofA Securities Biotech Conference

Dec 1, 2022, 4:05 PM EST - 2 years ago

Lyell Immunopharma to Participate in BofA Securities Biotech Conference

Lyell Immunopharma to Participate in Barclays Virtual Fireside Chat Series

Nov 10, 2022, 4:05 PM EST - 2 years ago

Lyell Immunopharma to Participate in Barclays Virtual Fireside Chat Series

Lyell Immunopharma Reports Recent Business Highlights and Third Quarter Financial Results

Nov 8, 2022, 4:05 PM EST - 2 years ago

Lyell Immunopharma Reports Recent Business Highlights and Third Quarter Financial Results

Lyell Immunopharma Presents New Data at SITC Highlighting its Growing Pipeline of T – Cell Reprogramming Technologies and Product Candidates Targeting Solid Tumors

Nov 7, 2022, 8:05 AM EST - 2 years ago

Lyell Immunopharma Presents New Data at SITC Highlighting its Growing Pipeline of T – Cell Reprogramming Technologies and Product Candidates Targeting Solid Tumors

Lyell Immunopharma Announces FDA Clearance of its IND for LYL845, a TIL Product Candidate Enhanced with its Novel Epigenetic Reprogramming Technology for Solid Tumors

Oct 6, 2022, 4:05 PM EDT - 3 years ago

Lyell Immunopharma Announces FDA Clearance of its IND for LYL845, a TIL Product Candidate Enhanced with its Novel Epigenetic Reprogramming Technology for Solid Tumors

Lyell Immunopharma to Present Preclinical Data Highlighting New T-Cell Reprogramming Technologies and its Growing Pipeline at 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Oct 5, 2022, 8:05 AM EDT - 3 years ago

Lyell Immunopharma to Present Preclinical Data Highlighting New T-Cell Reprogramming Technologies and its Growing Pipeline at 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Lyell Immunopharma Announces the Appointment of Rahsaan Thompson as Chief Legal Officer

Sep 28, 2022, 4:05 PM EDT - 3 years ago

Lyell Immunopharma Announces the Appointment of Rahsaan Thompson as Chief Legal Officer

Lyell Immunopharma Presents First in Human Trial Design of LYL797 at ESMO 2022

Sep 12, 2022, 3:00 AM EDT - 3 years ago

Lyell Immunopharma Presents First in Human Trial Design of LYL797 at ESMO 2022

Lyell Immunopharma to Participate in Morgan Stanley Global Healthcare Conference

Aug 30, 2022, 4:05 PM EDT - 3 years ago

Lyell Immunopharma to Participate in Morgan Stanley Global Healthcare Conference

Polip
Polip Jul. 9 at 1:59 PM
$LYEL sad to see Lyell left behind in this biotech comeback. it's going to be seen. It;s a matter of time. 140M market cap with 300M in the bank $XBI
1 · Reply
fantastex
fantastex Jul. 6 at 2:27 PM
$LYEL Is this the week?
0 · Reply
fantastex
fantastex Jul. 1 at 12:17 PM
$LYEL news or no volume here.. Let's
0 · Reply
Polip
Polip Jun. 30 at 12:39 PM
$ABBV buys CAPSTAN TX a pre clinical CAR T company for 2 Billion dollars. This is huge for other Car T and cell therapy companies. VALUATION RESET $LYEL $KYTX $IOVA
1 · Reply
fantastex
fantastex Jun. 28 at 6:13 PM
$LYEL on Friday It traded over 12x relative volume.....
0 · Reply
fantastex
fantastex Jun. 27 at 3:34 PM
$LYEL from -4% to over 9... Highly manipulated price. After 1st of July we go higher .
0 · Reply
fantastex
fantastex Jun. 27 at 2:35 PM
$LYEL as said by @Peterson28 we should be patient and wait for better news. I honestly think that we'll get some sort of partnership later this year and or buyout rumors (reverse merger with $BMY ). They can easily scoop up this company for 500m in a glance. My target is 35. (23+50%premium)
0 · Reply
Peterson28
Peterson28 Jun. 26 at 3:22 AM
$LYEL The only loss making position this year but I am a very patient investor. Still expect a pump to $100 this year.
1 · Reply
JarvisFlow
JarvisFlow Jun. 24 at 11:30 AM
HC Wainwright & Co. has updated their rating for Lyell Immunopharma ( $LYEL ) to Neutral with a price target of 10.
0 · Reply
QuiverQuant
QuiverQuant Jun. 23 at 11:16 PM
Lyell Immunopharma to Discuss Clinical Data on LYL314 at H.C. Wainwright's "HCW@Home" Series Read more on $LYEL: https://www.quiverquant.com/news/Lyell+Immunopharma+to+Discuss+Clinical+Data+on+LYL314+at+H.C.+Wainwright%27s+%22HCW%40Home%22+Series?utm_campaign=stocktwits
0 · Reply
Mdugs
Mdugs Jun. 23 at 7:16 PM
$LYEL I can’t stop buying at these levels or below
0 · Reply
GanymedeSpecial
GanymedeSpecial Jun. 20 at 7:58 PM
$LYEL ouch
0 · Reply
ASKING7
ASKING7 Jun. 20 at 7:38 PM
$LYEL Loading
0 · Reply
ScalpMantis
ScalpMantis Jun. 20 at 3:38 PM
$LYEL
0 · Reply
fantastex
fantastex Jun. 18 at 4:43 PM
$NKTR or $LYEL?
0 · Reply
Ned_Nosurname
Ned_Nosurname Jun. 17 at 11:09 PM
$LYEL $JNJ $GILD https://www.oncologypipeline.com/apexonco/lyell-takes-jj-and-gilead
3 · Reply
fantastex
fantastex Jun. 17 at 4:57 PM
$NKTR never been so convinced today about the good path forward. This and $LYEL are my biggest bets
1 · Reply
ASKING7
ASKING7 Jun. 17 at 1:58 PM
$LYEL Loading. We will see this is just lacked of interest or delayed price reaction soon
2 · Reply
Peterson28
Peterson28 Jun. 17 at 1:46 PM
$LYEL Interesting price reaction. No one really cares about the company. Sad.
1 · Reply
Mdugs
Mdugs Jun. 17 at 1:40 PM
$LYEL funny they released data a day before the presentation
0 · Reply
fantastex
fantastex Jun. 17 at 1:30 PM
$LYEL my TP here after the showcased results is 90$
0 · Reply
topstockalerts
topstockalerts Jun. 17 at 12:10 PM
$LYEL can she push higher?🏦📈🍾
0 · Reply